PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression

Yang,Wenxiu; Li,Yi; Li,Pinhao; Wang,Lingling

doi:10.3892/or.2016.4899

PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression

Authors:
- Wenxiu Yang
- Yi Li
- Pinhao Li
- Lingling Wang
View Affiliations

Affiliations: Department of Pathology, Affiliated Hospital, Guizhou Medical University, Guiyang, Guizhou 550001, P.R. China, Department of Pathology, Guizhou Medical University, Guiyang, Guizhou 550025, P.R. China
Published online on: June 22, 2016 https://doi.org/10.3892/or.2016.4899
Pages: 1069-1075

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma. A20 and mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) are known to be related to DLBCL pathogenesis and progression. This study aimed to assess the effects of phorbol myristate acetate/ionomycin (PMA/IONO) on the growth and apoptosis of the DLBCL cell line OCI-LY1, and their associations with A20, MALT1 and survivin levels. Cell viability was assessed by MTT assay. Cell cycle distribution and apoptosis were evaluated using flow cytometry after incubation with Annexin V-FITC/propidium iodide (PI) and RNase/PI, respectively. Gene and protein expression levels were determined by quantitative real-time PCR and western blotting, respectively. To further determine the role of A20, this gene was silenced in the OCI-LY1 cell line by specific siRNA transfection. A20 protein levels were higher in the OCI-LY1 cells treated with PMA/IONO compared with the controls, and were positively correlated with the concentration and treatment time of IONO, but not with changes of PMA and MALT1. Meanwhile, survivin expression was reduced in the OCI-LY1 cells after PMA/IONO treatment. In addition, OCI-LY1 proliferation was markedly inhibited, with a negative correlation between cell viability and IONO concentration. In concordance, apoptosis rates were higher in the OCI-LY1 cells after PMA + IONO treatment. Cell cycle distribution differed between the OCI-LY1 cells with and without PMA/IONO treatment only at 24 h, with increased cells in the G0/G1 stage after PMA/IONO treatment. These findings indicate that PMA/IONO promotes the apoptosis and inhibits the growth of DLBCL cells, in association with A20 upregulation. Thus, A20 may be a potential therapeutic target for DLBCL.

View Figures

View References

1	Menon MP, Pittaluga S and Jaffe ES: The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J. 18:411–420. 2012. View Article : Google Scholar : PubMed/NCBI
2	Pulvino M, Liang Y, Oleksyn D, DeRan M, Van Pelt E, Shapiro J, Sanz I, Chen L and Zhao J: Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood. 120:1668–1677. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ramachandiran S, Adon A, Guo X, Wang Y, Wang H, Chen Z, Kowalski J, Sunay UR, Young AN, Brown T, et al: Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway. Int J Cancer. 136:2341–2351. 2015. View Article : Google Scholar
4	Niu M, Shen Y, Xu X, Yao Y, Fu C, Yan Z, Wu Q, Cao J, Sang W, Zeng L, et al: Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import. Biochem Biophys Res Commun. 462:326–331. 2015. View Article : Google Scholar : PubMed/NCBI
5	Staudt LM: Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2:a0001092010. View Article : Google Scholar : PubMed/NCBI
6	Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, et al: Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 110:1398–1403. 2013. View Article : Google Scholar : PubMed/NCBI
7	Zhao Q, Fu W, Jiang H, Du J, Zhang C, Xi H, Zhou F, Li R and Hou J: Clinicopathological implications of nuclear factor κB signal pathway activation in diffuse large B-cell lymphoma. Hum Pathol. 46:524–531. 2015. View Article : Google Scholar : PubMed/NCBI
8	Afonina IS, Elton L, Carpentier I and Beyaert R: MALT1 - a universal soldier: Multiple strategies to ensure NF-κB activation and target gene expression. FEBS J. 282:3286–3297. 2015. View Article : Google Scholar : PubMed/NCBI
9	Martinez-Climent JA: The origin and targeting of mucosa-associated lymphoid tissue lymphomas. Curr Opin Hematol. 21:309–319. 2014. View Article : Google Scholar : PubMed/NCBI
10	Bavi P, Abubaker J, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Siraj AK and Al-Kuraya KS: Clinico-pathological significance of TNF alpha-induced protein3 (TNFAIP3) in Middle Eastern colorectal carcinoma. Clin Epigenetics. 2:417–418. 2011. View Article : Google Scholar
11	Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y and Seto M: TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 114:2467–2475. 2009. View Article : Google Scholar : PubMed/NCBI
12	Paik JH, Go H, Nam SJ, Kim TM, Heo DS, Kim CW and Jeon YK: Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: An analysis according to immunohistochemical subgroups and rituximab treatment. Leuk Lymphoma. 54:1934–1941. 2013. View Article : Google Scholar : PubMed/NCBI
13	Nakamura S and Matsumoto T: Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma: Recent progress in pathogenesis and management. World J Gastroenterol. 19:8181–8187. 2013. View Article : Google Scholar : PubMed/NCBI
14	Nocturne G, Boudaoud S, Miceli-Richard C, Viengchareun S, Lazure T, Nititham J, Taylor KE, Ma A, Busato F, Melki J, et al: Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood. 122:4068–4076. 2013. View Article : Google Scholar : PubMed/NCBI
15	Fontan L and Melnick A: Targeting lymphomas through MALT1 inhibition. Oncotarget. 3:1493–1494. 2012. View Article : Google Scholar
16	McAllister-Lucas LM, Baens M and Lucas PC: MALT1 protease: A new therapeutic target in B lymphoma and beyond? Clin Cancer Res. 17:6623–6631. 2011. View Article : Google Scholar : PubMed/NCBI
17	He C, Liu Z, Ji J and Zhu H: Prognostic value of survivin in patients with non-Hodgkin's lymphoma: A meta-analysis. Int J Clin Exp Med. 8:5847–5854. 2015.PubMed/NCBI
18	Sun L, Zhao Y, Shi H, Ma C and Wei L: LMP-1 induces survivin expression to inhibit cell apoptosis through the NF-κB and PI3K/Akt signaling pathways in nasal NK/T-cell lymphoma. Oncol Rep. 33:2253–2260. 2015.PubMed/NCBI
19	Abate D, Saldan A, Forner G, Tinto D, Bianchin A and Palù G: Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants. J Virol Methods. 196:157–162. 2014. View Article : Google Scholar
20	Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P and Beyaert R: T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol. 9:263–271. 2008. View Article : Google Scholar : PubMed/NCBI
21	Debernardis D, Stanzione S, Ottoboni C, Clerico L, Mancuso T, Parodi S and Russo P: Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines. J Pharmacol Exp Ther. 279:84–90. 1996.PubMed/NCBI
22	Zelenetz AD: Guidelines for NHL: Updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30⁺ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia. J Natl Compr Canc Netw. 12(Suppl 5): 797–800. 2014.PubMed/NCBI
23	Carbone A, Gloghini A, Kwong YL and Younes A: Diffuse large B cell lymphoma: Using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol. 93:1263–1277. 2014. View Article : Google Scholar : PubMed/NCBI
24	Busca A, Saxena M and Kumar A: Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis. J Biol Chem. 287:15118–15133. 2012. View Article : Google Scholar : PubMed/NCBI
25	Fritzenwanger M, Jung C, Franz M, Foerster M and Figulla HR: Immunomodulatory effects of cardiotrophin-1 on in vitro cytokine production of monocytes and CD4⁺ T-lymphocytes. Indian J Med Res. 136:471–476. 2012.PubMed/NCBI
26	Yee J, White RE, Anderton E and Allday MJ: Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expression. PLoS One. 6:e285062011. View Article : Google Scholar : PubMed/NCBI